Nieuwe alinea
SITE UNDER CONSTRUCTION
Taking care of vascular health
About Resiliun
RESILIUN is an emerging biopharmaceutical company dedicated to the research, development and commercialization of innovative proprietary pharmaceutical approaches for the prevention and treatment of human vascular disease, through a novel superior approach to regulation of vascular repair of our blood vessels.
RESILIUN’s leadership has a wealth of international, commercial and scientific experience. The Company has a collaborative, science-driven culture and has strong collaborations with key academic and research centers. Founded in 2018, RESILIUN is based in the Netherlands, within a network of collaborating research organizations throughout Europe and North-America.
Our Science
- RESILIUN has identified the central cause of human vascular disease.
- Many different dietary and life style conditions are responsible for causing human vascular diseases as atherosclerosis and diabetes. No central causal mechanism underlying these vascular conditions is ever recognized.
- RESILIUN has now identified and patented one overriding mechanism that explains vascular disease occurrence in humans: excessive activation of the human elastin receptor complex that causes excessive and perpetual vascular repair of our blood vessels. This excessive and perpetual repair is central to the chronic inflammatory state of blood vessels seen with atherosclerosis and diabetes. RESILIUN develops diagnostic and therapeutic approaches that identify and modulate these inflammatory mechanisms in humans.
Contact us
Please contact us for further information.
